Is FATIGUE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed FATIGUE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 300 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported FATIGUE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and FATIGUE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause FATIGUE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes FATIGUE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if FATIGUE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing FATIGUE: 300
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where FATIGUE is a reported side effect: 9.0117%

FDA reports of any drug causing FATIGUE : 140268
Average percentage for all medicated patients where FATIGUE is reported as a complication: 0.8791%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with FATIGUE:

TYSABRI (13629 patients)
ASPIRIN (10270 patients)
FOSAMAX (7993 patients)
HUMIRA (6731 patients)
AVONEX (6418 patients)
VIOXX (5986 patients)
ENBREL (5971 patients)
LIPITOR (5727 patients)
FORTEO (5286 patients)
SYNTHROID (4961 patients)
PREDNISONE (4581 patients)
LISINOPRIL (4570 patients)
ZOMETA (4473 patients)
SEROQUEL (4261 patients)
LASIX (3869 patients)
NEXIUM (3818 patients)
LYRICA (3638 patients)
SANDOSTATIN LAR (3550 patients)
COUMADIN (3493 patients)
METHOTREXATE (3427 patients)
NEURONTIN (3404 patients)
CHANTIX (3337 patients)
XANAX (3321 patients)
FOLIC ACID (3320 patients)
CYMBALTA (3176 patients)
SIMVASTATIN (3174 patients)
ATENOLOL (3076 patients)
AMBIEN (3059 patients)
HYDROCHLOROTHIAZIDE (3043 patients)
OMEPRAZOLE (3032 patients)
PEGASYS (3029 patients)
PAXIL (3022 patients)
VITAMIN D (3001 patients)
ZOLOFT (2970 patients)
PRILOSEC (2960 patients)
FUROSEMIDE (2925 patients)
LEVOTHYROXINE SODIUM (2923 patients)
RIBAVIRIN (2853 patients)
ACCUTANE (2824 patients)
DIGOXIN (2821 patients)
REVLIMID (2805 patients)
PLAVIX (2771 patients)
TOPROL-XL (2755 patients)
CRESTOR (2614 patients)
ZOCOR (2598 patients)
PROTONIX (2559 patients)
LEXAPRO (2551 patients)
NORVASC (2457 patients)
METFORMIN HCL (2448 patients)
ACETAMINOPHEN (2394 patients)
DEXAMETHASONE (2329 patients)
ALBUTEROL (2328 patients)
IBUPROFEN (2324 patients)
ATIVAN (2322 patients)
SOLIRIS (2302 patients)
REMICADE (2298 patients)
LORAZEPAM (2294 patients)
CELEBREX (2292 patients)
BYETTA (2203 patients)
CALCIUM (2193 patients)
PREVACID (2191 patients)
REBIF (2187 patients)
VICODIN (2132 patients)
AREDIA (2122 patients)
POTASSIUM CHLORIDE (2074 patients)
DIOVAN (2024 patients)
GABAPENTIN (2006 patients)
OXYCONTIN (1964 patients)
PREDNISONE TAB (1938 patients)
ALLOPURINOL (1934 patients)
NEXAVAR (1925 patients)
PERCOCET (1887 patients)
LEVAQUIN (1825 patients)
CLONAZEPAM (1821 patients)
METOPROLOL TARTRATE (1820 patients)
ADVAIR DISKUS 100/50 (1817 patients)
SINGULAIR (1808 patients)
EFFEXOR (1807 patients)
MULTI-VITAMINS (1804 patients)
HEPARIN SODIUM INJECTION (1750 patients)
COREG (1749 patients)
LANTUS (1721 patients)
PROZAC (1692 patients)
MULTI-VITAMIN (1675 patients)
GILENYA (1669 patients)
KLONOPIN (1644 patients)
DECADRON (1597 patients)
PREMARIN (1577 patients)
WARFARIN SODIUM (1566 patients)
ZOFRAN (1560 patients)
OXYCODONE HCL (1557 patients)
WELLBUTRIN (1548 patients)
ALPRAZOLAM (1498 patients)
AVANDIA (1487 patients)
CELEXA (1446 patients)
AMLODIPINE (1404 patients)
VITAMIN B-12 (1397 patients)
DURAGESIC-100 (1395 patients)
MORPHINE (1374 patients)
TRAMADOL HCL (1362 patients)
EXJADE (1350 patients)
ZYRTEC (1349 patients)
DIAZEPAM (1345 patients)
FISH OIL (1336 patients)
INSULIN (1329 patients)
COPEGUS (1325 patients)
BENADRYL (1323 patients)
SUTENT (1312 patients)
SPIRIVA (1306 patients)
LORTAB (1305 patients)
ZETIA (1293 patients)
PEG-INTRON (1286 patients)
TRAZODONE HCL (1258 patients)
STRATTERA (1238 patients)
ZANTAC (1233 patients)
VALIUM (1231 patients)
BETASERON (1229 patients)
LAMICTAL (1228 patients)
GLEEVEC (1222 patients)
XOLAIR (1217 patients)
SPIRONOLACTONE (1210 patients)
ASCORBIC ACID (1208 patients)
BACLOFEN (1200 patients)
LEVOXYL (1194 patients)
GLUCOPHAGE (1194 patients)
CISPLATIN (1181 patients)
TOPAMAX (1173 patients)
XELODA (1172 patients)
ARANESP (1165 patients)
VITAMIN E (1165 patients)
FLEXERIL (1135 patients)
CARBOPLATIN (1132 patients)
METOPROLOL (1126 patients)
ZYPREXA (1120 patients)
CIMZIA (1109 patients)
ALLEGRA (1098 patients)
AMOXICILLIN (1092 patients)
EFFEXOR XR (1090 patients)
COZAAR (1084 patients)
COMPAZINE (1070 patients)
ACTOS (1058 patients)
VELCADE (1054 patients)
NITROGLYCERIN (1035 patients)
PRISTIQ (1035 patients)
FLOMAX (1031 patients)
TYLENOL (1030 patients)
RISPERDAL (1027 patients)
CALCIUM CARBONATE (1021 patients)
NIASPAN (1012 patients)
MIRENA (1006 patients)
CYCLOPHOSPHAMIDE (1006 patients)
ARIMIDEX (1001 patients)
FLONASE (994 patients)
GLIPIZIDE (991 patients)
TYLENOL (CAPLET) (985 patients)
PROCRIT (984 patients)
KEPPRA (978 patients)
ALENDRONATE SODIUM (968 patients)
FENTANYL (956 patients)
COLACE (948 patients)
FLUOROURACIL (945 patients)
LOVENOX (928 patients)
ALTACE (923 patients)
YAZ (917 patients)
RANITIDINE (914 patients)
PREDNISOLONE (913 patients)
BONIVA (912 patients)
PROVIGIL (912 patients)
CIPROFLOXACIN (911 patients)
METFORMIN (908 patients)
ENALAPRIL MALEATE (905 patients)
AMITRIPTYLINE HCL (901 patients)
ACTONEL (901 patients)
CARVEDILOL (896 patients)
CITALOPRAM HYDROBROMIDE (894 patients)
TAXOTERE (892 patients)
PAROXETINE HCL (891 patients)
FEMARA (878 patients)
IRON (872 patients)
ZITHROMAX (860 patients)
METOPROLOL SUCCINATE (860 patients)
GLYBURIDE (852 patients)
AVASTIN (848 patients)
HYDROCODONE (840 patients)
TRICOR (834 patients)
RAMIPRIL (822 patients)
PRADAXA (820 patients)
CLARITIN (820 patients)
FERROUS SULFATE TAB (818 patients)
LOPRESSOR (815 patients)
PANTOPRAZOLE (812 patients)
ACYCLOVIR (812 patients)
PRAVASTATIN (804 patients)
CLONIDINE (803 patients)
YASMIN (802 patients)
PEPCID (799 patients)
DEPAKOTE (799 patients)
NAPROXEN (796 patients)
ALDACTONE (793 patients)
PACLITAXEL (792 patients)
INCIVEK (785 patients)
KETEK (784 patients)
NAMENDA (779 patients)
REGLAN (778 patients)
ULTRAM (778 patients)
DILAUDID (777 patients)
MORPHINE SULFATE (772 patients)
POTASSIUM (766 patients)
HUMALOG (765 patients)
LANSOPRAZOLE (763 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about FATIGUE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.